New Drug Approvals Archive

Get news by email or subscribe to our news feeds.

September 2013

September 6

Abraxane (paclitaxel protein-bound)

New Indication Approved: September 6, 2013

Abraxane (paclitaxel protein-bound) FDA Approval History

September 11

Botox Cosmetic (onabotulinumtoxinA)

New Indication Approved: September 11, 2013

September 23

Stelara (ustekinumab)

New Indication Approved: September 20, 2013

Stelara (ustekinumab) FDA Approval History

September 24

Butrans (buprenorphine)

New Dosage Regimen: September 24, 2013

Butrans (buprenorphine) FDA Approval History

September 30

Cimzia (certolizumab pegol)

New Indication Approved: September 27, 2013

Cimzia (certolizumab pegol) FDA Approval History

September 30

Perjeta (pertuzumab)

New Indication Approved: September 30, 2013

Perjeta (pertuzumab) FDA Approval History

September 30

Brintellix (vortioxetine) Tablets

Date of Approval: September 30, 2013
Company: Takeda Pharmaceutical Company Limited and H. Lundbeck A/S
Treatment for: Depression

Brintellix (vortioxetine) is a multimodal antidepressant for the treatment of major depressive disorder (MDD).

Brintellix (vortioxetine) FDA Approval History

Hide
(web1)